BD and ChemoGLO announced a strategic collaboration to broaden hazardous‑drug contamination testing in healthcare settings. The partnership combines BD’s rapid, point‑of‑care BD HD Check System—capable of delivering qualitative results in 10 minutes—with ChemoGLO’s liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) platform, which provides a comprehensive quantitative report on an expanded panel of hazardous drugs within three to five days after sample receipt.
The integrated workflow allows facilities to quickly identify potential contamination using the HD Check kit and then ship samples to ChemoGLO for precise LC‑MS/MS analysis. This two‑step approach delivers both speed and depth, enabling healthcare providers to act faster while obtaining detailed exposure data that aligns with the 2020 Safe to Touch Consensus Conference recommendations for hazardous‑drug surface contamination testing.
BD’s Q3 2025 revenue reached $5.5 billion, with an adjusted diluted EPS of $3.68, and Q4 2025 revenue rose to $5.9 billion, with an adjusted diluted EPS of $3.96. The collaboration fits within BD’s safety‑solutions portfolio, a key component of the BD Medical segment, and is expected to strengthen the segment’s growth trajectory by adding a new service offering that could generate additional revenue and deepen customer relationships in hospitals, pharmacies, and laboratories.
"With the BD® HD Check System, facilities can quickly identify potential contamination, and through our collaboration with ChemoGLO™, gain deeper insights into exposure risks," said Eric Borin, worldwide president of BD Medication Delivery Solutions. "By combining speed and precision, we help facilities act faster and more confidently to safeguard their teams," added Cara Zamboni, CEO of ChemoGLO.
The partnership positions BD to meet growing regulatory and patient‑safety demands, potentially increasing market share in the niche but critical hazardous‑drug testing segment. While specific financial projections for the collaboration are not disclosed, the added service is expected to enhance BD’s competitive edge and support its broader strategy of expanding high‑margin safety solutions.
Both companies will showcase the collaboration at the American Society of Health‑System Pharmacists Midyear Clinical Meeting in Las Vegas from December 6‑10, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.